Publicaciones científicas

4 Publicaciones científicas disponibles

  • Performance Comparison of Two Next-Generation Sequencing Panels to Detect Actionable Mutations in Cell-Free DNA in Cancer Patients

    28 de julio de 2020 | Revista: Clinical Chemistry and Laboratory Medicine

    Mónica Macías  (1) , Eva Cañada-Higueras  (2) , Estibaliz Alegre  (1, 3) , Arancha Bielsa  (2) , Javier Gracia  (2) , Ana Patiño-García  (2, 3, 4) , Roser Ferrer-Costa  (5) , Teresa Sendino  (1) , María P Andueza  (6) , Beatriz Mateos (1) , Javier Rodríguez  (3, 6) , Jesús Corral  (2) , Alfonso Gúrpide  (3, 6) , José M Lopez-Picazo  (3, 6) , Jose L Perez-Gracia  (3, 6) , Ignacio Gil-Bazo  (3, 6, 7, 8) , Gorka Alkorta-Aranburu (2) , Álvaro González  (1, 3)

    (1) Service of Biochemistry, Clínica Universidad de Navarra, Pamplona, Spain.
    (2) CIMA LAB Diagnostics Universidad de Navarra, Pamplona, Spain.
    (3) IdiSNA, Navarra Institute for Health Research, Pamplona, Spain.
    (4) Department of Pediatrics, Clínica Universidad de Navarra, Pamplona, Spain.
    (5) Department of Biochemistry, Hospital Universitari Vall D'Hebron, Universitat Autònoma De Barcelona, Barcelona, Spain.
    (6) Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain.
    (7) Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
    (8) Program of Solid Tumors, Center for Applied Medical Research, University of Navarra, Pamplona, Spain.


  • PD-1/PD-L1 blockers in NSCLC brain metastases: challenging paradigms and clinical practice

    30 de abril de 2020 | Revista: Clinical Cancer Research

    Eguren-Santamaria I (1), Sanmamed MF (2), Goldberg SB (3), Kluger HM (4), Idoate MA (5), Lu BY (3), Corral J (1), Schalper KA (6), Herbst RS (3), Gil-Bazo I (7).

    (1) Department of Oncology, Clínica Universidad de Navarra.
    (2) Department of Immunobiology, Yale School of Medicine.
    (3) Department of Medicine (Section of Medical Oncology), Yale School of Medicine.
    (4) Smilow Cancer Center, Yale School of Medicine.
    (5) Department of Pathology, Clínica Universidad de Navarra, University of Navarraniversity of Navarra, Pamplona, Spain.
    (6) Department of Pathology, Yale School of Medicine.
    (7) Department of Oncology, Clínica Universidad de Navarra igbazo@unav.es.


  • Effects of dose modifications on the safety and efficacy of dacomitinib for EGFR mutation-positive non-small-cell lung cancer

    17 de julio de 2019 | Revista: Future Oncology

    Corral J (1), Mok TS (2), Nakagawa K (3), Rosell R (4), Lee KH (5), Migliorino MR (6), Pluzanski A (7), Linke R (8), Devgan G (9), Tan W (10), Quinn S (11), Wang T (12), Wu YL (13).

    (1) Clínica Universidad de Navarra, Madrid, 28027, Spain.
    (2) State Key Laboratory of South China, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong, PR China.
    (3) Kindai University Hospital, Osaka, 589-8511, Japan.
    (4) Catalan Institute of Oncology, Barcelona, Spain.
    (5) Chungbuk National University Hospital, Cheongju, Korea.
    (6) Pulmonary Oncology Unit, San Camillo-Forlanini Hospital, Rome, 00152, Italy.
    (7) The Maria Sklodowska-Curie Memorial Cancer Centre & Institute of Oncology, Warsaw, 02-781, Poland.
    (8) SFJ Pharmaceuticals®, Pleasanton, CA 94588, USA.
    (9) Pfizer Oncology, New York, NY 10017, USA.
    (10) Pfizer Clinical Pharmacology, San Diego, CA 92121, USA.
    (11) Pfizer Oncology, Cambridge, MA 02139, USA.
    (12) Pfizer Oncology, Groton, CT 06340, USA.
    (13) Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, 510080, PR China.


  • Management of common adverse events related to first-line dacomitinib use in EGFR mutation-positive non-small-cell lung cancer

    15 de mayo de 2019 | Revista: Future Oncology

    Zhou Q (1), Wu YL (1), Corral J (2), Nakagawa K (3), Garon EB (4), Sbar EI (5), Wang T (6), Sandin R (7), Noonan K (6), Gernhardt D (6), Mok TS (8).

    (1) Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, 510080, PR China.
    (2) Clínica Universidad de Navarra, Madrid, 28027, Spain.
    (3) Kindai University Hospital, Osaka, 589-8511, Japan.
    (4) David Geffen School of Medicine, University of California at Los Angeles, Santa Monica, CA 90404, USA.
    (5) Pfizer Inc., Collegeville, PA 19426, USA.
    (6) Pfizer Inc., Groton, CT 06340, USA.
    (7) Pfizer Inc., Sollentuna, 191 38, Sweden.
    (8) State Key Laboratory of South China, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong, PR China.